SF3B1  mutation is a prognostic factor in chronic lymphocytic leukemia: a meta-analysis

Zhenghao Zhang; Shu Chen; Shuang Chen; Gang Chen; Rui Zhang; Jinhua Li; Jianhua Qu

doi:10.18632/oncotarget.19455

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

SF3B1 mutation is a prognostic factor in chronic lymphocytic leukemia: a meta-analysis

Zhenghao Zhang, Shu Chen, Shuang Chen, Gang Chen, Rui Zhang, Jinhua Li and Jianhua Qu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:69916-69923. https://doi.org/10.18632/oncotarget.19455

Metrics: PDF 2075 views | HTML 2143 views | ?

Abstract

Zhenghao Zhang1, Shu Chen2, Shuang Chen1, Gang Chen1, Rui Zhang1, Jinhua Li1 and Jianhua Qu1

1Centre of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China

2Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China

Correspondence to:

Jianhua Qu, email: [email protected]

Keywords: SF3B1, chronic lymphocytic leukemia, prognosis, survival, meta-analysis

Received: December 01, 2016 Accepted: May 27, 2017 Published: July 22, 2017

ABSTRACT

Recent studies suggest that SF3B1 might be related to poor prognosis in CLL, but the results remain controversial. This meta-analysis was performed to clarify the relationship between SF3B1 mutation and prognosis in patients with CLL. The relevant published reports were searched in PubMed, EMBASE, and Web of Science. A total of 13 articles were included in this meta-analysis as they met the inclusion and exclusion criteria. The hazard ratios (HRs) and corresponding 95% confidence intervals (95%CIs) for progression free survival (PFS) and/or overall survival (OS) were extracted from each eligible study. The pooled HR evaluating SF3B1 mutation on PFS was 1.81(95%CI 1.33-2.46, I²=78.9%, P<0.001) and on on OS was 2.57(95%CI 1.68-3.94, I²=79.3%, P<0.001) by random effects model. In conclusion, SF3B1 mutation was significantly associated with poor PFS and OS in CLL. It could be consider as a potential prognostic factor in patients with CLL.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19455

Publication Alerts

Research Papers:

SF3B1 mutation is a prognostic factor in chronic lymphocytic leukemia: a meta-analysis

Abstract